PureTech Health PLC PTCHF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PTCHF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.64
- Day Range
- $2.68–2.68
- 52-Week Range
- $1.69–3.10
- Bid/Ask
- $2.57 / $2.75
- Market Cap
- $723.47 Mil
- Volume/Avg
- 50,000 / 36,517
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 435.07
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 4.30%
Company Profile
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 111
- Website
- https://www.puretechhealth.com
Comparables
Valuation
|
Metric
|
PTCHF
|
RYTM
|
QURE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.42 | 13.90 | 1.05 |
Price/Sales | 435.07 | 29.58 | 13.72 |
Price/Cash Flow | — | — | — |
Price/Earnings
PTCHF
RYTM
QURE
Financial Strength
|
Metric
|
PTCHF
|
RYTM
|
QURE
|
|---|---|---|---|
Quick Ratio | 7.19 | 5.27 | 8.44 |
Current Ratio | 7.31 | 5.58 | 8.85 |
Interest Coverage | −8.09 | −13.26 | −6.85 |
Quick Ratio
PTCHF
RYTM
QURE
Profitability
|
Metric
|
PTCHF
|
RYTM
|
QURE
|
|---|---|---|---|
Return on Assets (Normalized) | −21.43% | −46.12% | −35.54% |
Return on Equity (Normalized) | −29.05% | −76.97% | −82.34% |
Return on Invested Capital (Normalized) | −27.92% | −76.40% | −55.12% |
Return on Assets
PTCHF
RYTM
QURE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cqzkncbgnt | Xqrrp | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vhyfrmgp | Tygrfj | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cqrppjq | Hvrsv | $99.5 Bil | |
MRNA
| Moderna Inc | Jfrwwxxhq | Dwws | $38.8 Bil | |
ARGX
| argenx SE ADR | Zydylly | Nflc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fjzxmxgm | Kzj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qkjnxpbd | Mhwrp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hkmlnkp | Zpxjdmf | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zsyynrswnq | Xlvsls | $12.5 Bil | |
INCY
| Incyte Corp | Qrlpvfgn | Lbkhbp | $11.6 Bil |